Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus paclitaxel–platinum in recurrent or metastatic cervical cancer
CTR20212954Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in Cervical Cancer (CC), sponsored by Qilu Pharmaceutical. Primary endpoint: Safety endpoints. Started Aug 2022; status: completed.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20212954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212954.